Bal A et al (2007) Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26(2):211–215

Article  CAS  PubMed  Google Scholar 

Birner P et al (2016) Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. Exp Dermatol 25(4):305–310

Article  CAS  PubMed  PubMed Central  Google Scholar 

Birney E (2022) Mendelian randomization. Cold Spring Harb Perspect Med 12(4)

Brion MJ, Shakhbazov K, Visscher PM (2013) Calculating statistical power in mendelian randomization studies. Int J Epidemiol 42(5):1497–1501

Article  PubMed  Google Scholar 

Campbell IL et al (1991) Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 87(2):739–742

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi JS, Kim KH, Lau LF (2015) The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol 8(6):1285–1296

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coskun M, Vermeire S, Nielsen OH (2017) Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci 38(2):127–142

Article  CAS  PubMed  Google Scholar 

Davey Smith G, Hemani G (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23(R1):R89–98

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies NM, Holmes MV, Davey Smith G (2018) Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362:k601

Article  PubMed  PubMed Central  Google Scholar 

Dimitrov S et al (2006) Sleep enhances IL-6 trans-signaling in humans. Faseb j 20(12):2174–2176

Article  CAS  PubMed  Google Scholar 

Felten R et al (2021) Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis 80(3):329–338

Article  CAS  PubMed  Google Scholar 

Garbers C et al (2012) Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 23(3):85–97

Article  CAS  PubMed  Google Scholar 

Gay J et al (2006) Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines. Neuroimmunomodulation 13(2):114–121

Article  CAS  PubMed  Google Scholar 

Giambartolomei C et al (2014) Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 10(5):e1004383

Article  PubMed  PubMed Central  Google Scholar 

Greenbaum CJ, et al (2021) IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight 6(21)

Gross V et al (1992) Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease. Gastroenterology 102(2):514–519

Article  CAS  PubMed  Google Scholar 

Guo C et al (2020) Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun 11(1):3924

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanioka Y et al (2021) Exacerbation of Ulcerative Colitis with Tocilizumab: a report of two cases, one with Takayasu Arteritis and the other with relapsing polychondritis. Intern Med 60(10):1615–1620

Article  PubMed  Google Scholar 

Hibi M et al (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63(6):1149–1157

Article  CAS  PubMed  Google Scholar 

Hsu HC et al (2021) Systemic lupus erythematosus is associated with impaired autophagic degradation via interleukin-6 in macrophages. Biochim Biophys Acta Mol Basis Dis 1867(2):166027

Article  CAS  PubMed  Google Scholar 

Ito H (2005) Treatment of Crohn’s disease with anti-IL-6 receptor antibody. J Gastroenterol 40:32–34

Article  CAS  PubMed  Google Scholar 

Jandus C et al (2008) Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 58(8):2307–2317

Article  PubMed  Google Scholar 

Jia D, Zhang F, Li H, Shen Y, Jin Z, Shi FD, Zhang C (2023) Responsiveness to tocilizumab in anti-acetylcholine receptor-positive generalized myasthenia gravis. Aging Dis

Jonsson DI, Pirskanen R, Piehl F (2017) Beneficial effect of tocilizumab in myasthenia gravis refractory to Rituximab. Neuromuscul Disord 27(6):565–568

Article  PubMed  Google Scholar 

Kallaur AP et al (2013) Cytokine profile in relapsing–remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep 7(3):1010–1020

Article  CAS  PubMed  Google Scholar 

Kaneko Y, Takeuchi T (2021) An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine 146:155645

Article  CAS  PubMed  Google Scholar 

Kastrati K et al (2022) A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 8(2):e002359

Article  PubMed  PubMed Central  Google Scholar 

Lee HI et al (2022) IL-6 activates pathologic Th17 cell via STAT 3 phosphorylation in inflammatory joint of Ankylosing Spondylitis. Biochem Biophys Res Commun 620:69–75

Article  CAS  PubMed  Google Scholar 

Mallalieu NL et al (2019) Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatr Rheumatol Online J 17(1):57

Article  PubMed  PubMed Central  Google Scholar 

Merashli M et al (2016) Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis. Ann Rheum Dis 75(7):1418–1420

Article  CAS  PubMed  Google Scholar 

Naito Y et al (2004) Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int J Mol Med 14(2):191–196

CAS  PubMed  Google Scholar 

Nakahara H et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48(6):1521–1529

Article  CAS  PubMed  Google Scholar 

Nishihara M et al (2007) IL-6-gp130-STAT3 in T cells directs the development of IL-17 + th with a minimum effect on that of Treg in the steady state. Int Immunol 19(6):695–702

Article  CAS  PubMed  Google Scholar 

Okiyama N et al (2009) Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60(8):2505–2512

Article  CAS  PubMed  Google Scholar 

Papadimitriou N et al (2020) Physical activity and risks of breast and colorectal cancer: a mendelian randomisation analysis. Nat Commun 11(1):597

Article  CAS